title: Obstacles to the development of a safe and effective attenuated pre-erythrocytic stage malaria vaccine.
abstract: Attenuated pre-erythrocytic stage malaria vaccines protect humans from sporozoite challenge. Current technology limits the feasibility of their commercial scale production and poses a significant risk of contamination with transmissible agents. Overcoming these barriers will be very challenging. In contrast, subunit vaccines appear quite feasible and show great promise as candidate malaria vaccines.
authors.affiliation: Worldwide Clinical Development, GlaxoSmithKline Biologicals, Rue de l'Institut 89, 1330 Rixensart, Belgium. ripley.ballou@gskbio.com
authors.forename: W
authors.initials: W
authors.lastname: Ripley Ballou
mesh_terms: D000818:Animals; D015195:Drug Design; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000737:chemistry / Q000276:immunology; D010961:Plasmodium / Q000502:physiology; D015800:Protozoan Proteins / Q000737:chemistry / Q000276:immunology; D034101:Sporozoites / Q000276:immunology; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic / Q000737:chemistry / Q000276:immunology
chemical_list: D017780:Malaria Vaccines; D015800:Protozoan Proteins; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic